Summary
Elevance Health, Inc. (then operating as WellPoint, Inc.) filed an 8-K on August 12, 2010, to report on the significant issuance of long-term debt. The company successfully sold $700 million in 4.350% Notes due 2020 and $300 million in 5.800% Notes due 2040, raising a total of approximately $986.5 million in net proceeds after underwriting discounts and expenses. These proceeds are earmarked for working capital and general corporate purposes, including the repayment of existing debt, indicating a strategic move to strengthen its capital structure and potentially lower its cost of borrowing. The issuance of these notes, registered under the Securities Act of 1933, provides WellPoint with substantial long-term financing. The filing details the terms of the notes, including interest payment schedules, maturity dates, and conditions for default. Notably, the company has the option to redeem these notes under certain conditions and must offer to repurchase them at 101% of principal if a change of control occurs concurrently with a credit rating downgrade, providing a degree of protection for noteholders.
Key Highlights
- 1WellPoint, Inc. (now Elevance Health) issued $1 billion in aggregate principal amount of new notes.
- 2The issuance consisted of $700 million in 4.350% Notes due 2020 and $300 million in 5.800% Notes due 2040.
- 3Net proceeds from the offering totaled approximately $986.5 million.
- 4The company intends to use the proceeds for working capital, general corporate purposes, and debt repayment.
- 5The notes were issued under an Indenture dated January 10, 2006, with The Bank of New York Mellon Trust Company, N.A. as trustee.
- 6The terms include provisions for redemption at the company's option and a change of control offer to repurchase at 101% under specific downgrade conditions.
- 7The filing establishes WellPoint's financial obligations related to these new debt instruments.